Table 5 |
||||||
|
Haplotype trend regression in rheumatoid arthritis patients and healthy controls for FCGR3A-FCGR3B haplotypes |
||||||
|
Haplotype |
UK Caucasian |
North Indian/Pakistani |
||||
|
|
||||||
|
RA |
P |
Nodular RA |
P |
RA |
P |
|
|
158F-NA2 |
1 (baseline) |
- |
1 (baseline) |
- |
1 (baseline) |
- |
|
158F-NA1 |
1.62 (0.99–2.66) |
0.05 |
1.58 (0.67–3.70) |
0.29 |
0.96 (0.60–1.54) |
0.85 |
|
158V-NA2 |
1.77 (1.09–2.87) |
0.02 |
2.51 (1.15–5.49) |
0.02 |
1.52 (0.82–2.80) |
0.19 |
|
158V-NA1 |
1.44 (0.61–3.40) |
0.41 |
2.00 (0.63–6.39) |
0.24 |
1.22 (0.63–2.37) |
0.55 |
|
|
||||||
|
Values are expressed as odds ratio (95% confidence interval). RA, rheumatoid arthritis. |
||||||
|
Morgan et al. Arthritis Research & Therapy 2006 8:R5 doi:10.1186/ar1847 |
||||||
